AACE AND ACE
POSITION STATEMENT ON MENOPAUSE–2017 UPDATE

1. Recommendation: the use of menopausal hormone therapy in symptomatic postmenopausal women should be based on consideration of all risk factors for cardiovascular disease, age, and time from menopause.

2. Recommendation: the use of transdermal as compared with oral estrogen preparations may be considered less likely to produce thrombotic risk and perhaps the risk of stroke and coronary artery disease.

3. Recommendation: when the use of progesterone is necessary, micronized progesterone is considered the safer alternative.

4. Recommendation: in symptomatic menopausal women who are at significant risk from the use of hormone replacement therapy, the use of selective serotonin re-uptake inhibitors and possibly other nonhormonal agents may offer significant symptom relief.

5. Recommendation: AACE does not recommend use of bioidentical hormone therapy.

6. Recommendation: AACE fully supports the recommendations of the Comité de l'Évolution des Pratiques en Oncologie regarding the management of menopause in women with breast cancer.

7. Recommendation: HRT is not recommended for the prevention of diabetes.

8. Recommendation: In women with previously diagnosed diabetes, the use of HRT should be individualized, taking in to account age, metabolic, and cardiovascular risk factors.